On April 3, 2018, Pfizer and Allogene Therapeutics, a biotechnology company, announced that they have entered into an asset contribution agreement, under which Pfizer will transfer assets related to allogeneic chimeric antigen receptor T-cell (CAR-T) therapy in its portfolio to Allogene.
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.